Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Dostarlimab by GSK for Vulvar Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...
Dostarlimab by GSK for Hepatocellular Carcinoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II...
Dostarlimab by GSK for Vaginal Cancer: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II...
Maraviroc by GSK for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Likelihood of Approval
Maraviroc is under clinical development by GSK and currently in Phase III for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). According...
Daprodustat by GSK for Anemia in Chronic Kidney Disease (Renal Anemia): Likelihood of Approval
Daprodustat is under clinical development by GSK and currently in Phase III for Anemia in Chronic Kidney Disease (Renal Anemia)....
Niraparib by GSK for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...
Niraparib by GSK for Metastatic Melanoma: Likelihood of Approval
Niraparib is under clinical development by GSK and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...
Belantamab mafodotin by GSK for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Multiple Myeloma (Kahler Disease). According to...
Belantamab mafodotin by GSK for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
Belantamab mafodotin by GSK for Refractory Multiple Myeloma: Likelihood of Approval
Belantamab mafodotin is under clinical development by GSK and currently in Phase III for Refractory Multiple Myeloma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of GSK's GSK-4178116A?
GSK-4178116A is a live attenuated vaccine commercialized by GSK, with a leading Phase II program in Chicken Pox. According to...
Risk adjusted net present value: What is the current valuation of GSK's Depemokimab?
Depemokimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Hypereosinophilic Syndrome. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of GSK's AFX-3772?
AFX-3772 is a conjugate vaccine commercialized by GSK, with a leading Phase II program in Streptococcal Pneumonia. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of GSK's Men ABCWY?
Men ABCWY is a conjugate vaccine commercialized by GSK, with a leading Pre-Registration program in Neisseria meningitidis Infections. According to...
Risk adjusted net present value: What is the current valuation of GSK's Gepotidacin Mesylate?
Gepotidacin Mesylate is a small molecule commercialized by GSK, with a leading Phase III program in Urinary Tract Infections. According...
Risk adjusted net present value: What is the current valuation of GSK's GSK-3943104A?
GSK-3943104A is a subunit vaccine commercialized by GSK, with a leading Phase II program in Genital Herpes. According to Globaldata,...
Feladilimab by GSK for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...
Feladilimab by GSK for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Feladilimab is under clinical development by GSK and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to...
Risk adjusted net present value: What is the current valuation of GSK's Linerixibat?
Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it...
Risk adjusted net present value: What is the current valuation of GSK's Cobolimab?
Cobolimab is a monoclonal antibody commercialized by GSK, with a leading Phase III program in Non-Small Cell Lung Carcinoma;Squamous Non-Small...